Please assess the completion status of the following clinical trial:

Trial Title: Hemodynamic Response of Neuropathic And Non-Neuropathic POTS Patients To Adrenoreceptor Agonist And Antagonist

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE1/PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* CDC criteria for chronic fatigue syndrome~* Evidence of postural tachycardia syndrome with symptoms of orthostatic intolerance~Exclusion Criteria:~* Pregnant or lactating females. The administration of droxidopa is harmful to the fetus~* Concomitant therapy with anticholinergic, alpha-, and beta-adrenergic antagonists or other medications that affect autonomic function~* Clinically significant coronary artery, cerebrovascular or peripheral vascular disease~* Cardiac arrhythmias~* Systemic illness that might affect autonomic function such as congestive heart failure, hypertension, renal, pulmonary, and hepatic disease, anemia, malignancies, thyroid disease, and alcoholism~* Severe depression, severe anxiety disorder (score of on the Beck Depression Inventory \> 29 or score on the Beck Anxiety Inventory of ≥ 36) or psychosis~* Antidepressant treatment by MAO inhibitors within 2 weeks before the study~* Glaucoma~* Liver disease~* Subjects with a history of reaction to local anesthetic will be excluded from the study~* Subjects who have a history of any bleeding disorders or significantly impaired wound healing will be excluded. Subjects who are using any medications such as Coumadin or Plavix will be also excluded~* Subjects who are currently enrolled in any other studies using investigational products

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: f

Study Arms:
- Atenolol (Type: OTHER): In this arm subjects are randomized to atenolol 50 mg qd, droxidopa 100 mg/300 mg tid and placebo tid.~Atenolol is used to examine the effect of non-selective beta adrenoreceptor antagonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia patients.~Droxidopa is used to examine the effect of direct alpha-1 adrenoreceptor agonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia (POTS) patients.
- Placebos (Type: OTHER): In this arm subjects are randomized to placebo tid.~Placebo is used to control the administration effect.
- Droxidopa (Type: OTHER): In this arm subjects are randomized to droxidopa 100 mg/300 mg tid, atenolol 50 mg qd, and placebo tid.~Atenolol is used to examine the effect of non-selective beta adrenoreceptor antagonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia patients.~Droxidopa is used to examine the effect of direct alpha-1 adrenoreceptor agonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia (POTS) patients.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues